Citius Pharmaceuticals Files 8-K
Ticker: CTXR · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1506251
Sentiment: neutral
Topics: disclosure, financials, sec-filing
TL;DR
Citius Pharma filed an 8-K, likely containing financial updates or other material info.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on November 25, 2024, reporting other events and financial statements. The filing does not contain specific details about new events, material agreements, or financial results, but serves as a notification of these items being filed.
Why It Matters
This filing indicates that Citius Pharmaceuticals has submitted required disclosures to the SEC, which may include updates on their financial status or other material events.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not appear to contain negative news or significant changes.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 001-38174 (filing_id) — Commission File Number
- 27-3425913 (tax_id) — IRS Employer Identification No.
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
- November 25, 2024 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Citius Pharmaceuticals, Inc. in this 8-K filing?
The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the provided text.
What is the significance of filing 'Financial Statements and Exhibits' as part of this 8-K?
Filing 'Financial Statements and Exhibits' means the company is providing updated financial information and supporting documents as required by the SEC.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on November 25, 2024.
What is Citius Pharmaceuticals, Inc.'s state of incorporation and principal executive office address?
Citius Pharmaceuticals, Inc. is incorporated in Nevada and its principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Does this 8-K filing reveal any new material agreements or changes in executive compensation?
The provided text for the 8-K filing does not specify details regarding material agreements or executive compensation changes.
Filing Stats: 438 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-11-25 17:15:08
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea0222478-8k_citius.htm (8-K) — 23KB
- ea022247801ex99-1_citius.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-24-102265.txt ( ) — 227KB
- ctxr-20241125.xsd (EX-101.SCH) — 3KB
- ctxr-20241125_lab.xml (EX-101.LAB) — 33KB
- ctxr-20241125_pre.xml (EX-101.PRE) — 22KB
- ea0222478-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 25, 2024, we issued a press release announcing a productive Type C meeting with the U.S. Food and Drug Administration to discuss our Phase 3 clinical trial of Mino-Lok in patients with central line-associated infections or catheter-related bloodstream infections and a pathway to approval. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated November 25, 2024. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: November 25, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2